Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

The phase 3 IMforte study randomised adults with extensive-stage SCLC to receive Roche’s PD-L1 inhibitor Tecentriq ...

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

<li /> 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with ...